You are here

NIDDK RFA - Comorbidities and Cure

Thursday, September 3, 2020

NIDDK has recently published two RFAs:

RFA-DK-20-022, “Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)”

RFA-DK-20-023, “Toward ElucidAting MechanismS Contributing to HIV Reservoirs in NIDDK-relevant Tissues (Cure TEAMS) (R01 Clinical Trial Optional)”

Please note that each RFA requires an MPI structure. At least one PI must have expertise in HIV science and at least one PI must have expertise in physiology, pathophysiology, pathobiology, or metabolism.

Also, there are additional instructions for the Research Plan and the Multi PD/PI Leadership Plan under the PHS398 Research Plan Instructions heading for each RFA.:

Research Strategy:

The presentation of preliminary data must include a brief description of each PD/PI's contribution to it, which may be related to experimental design, execution, or interpretation.

Multiple PD/PI Leadership Plan:

The Multiple PD/PI leadership plan must include one or more examples of how development of specific aspects of the research plan benefited from interactions between the PDs /PIs. The plan should also describe how each PD/PI will participate in aspects of the project primarily led by the other PD(s)/PI(s) in order to leverage the full combined expertise of the Multiple PD/PI team.

How you address these requirements is scorable. Peer reviewers will address the following with their evaluation of Investigators:

Did the PD/PIs interact effectively during the preparation of the project? Does the described Multiple-PD/PI structure provide for appropriate participation of each PD/PI in aspects of the project primarily led by the other PD/PI(s), so that the project will benefit fully from the combined expertise of the Multiple PD/PI team?

Peer reviewers will address the following with their evaluation of the Approach: Do the preliminary data reflect productive interactions between the PDs/PIs?